Tvardi Therapeutics Alternatives & Competitors
12 companies similar to Tvardi Therapeutics — Breakthrough Medicines for Cancer, Chronic Inflammation & Fibrosis
Companies similar to Tvardi Therapeutics
Pharvaris
Pioneering science for patient choice
Zug, Switzerland
HepaRegeniX GmbH
Unlocking liver regeneration - delivering recovery
Tubingen, Germany
Redx Pharma
Biotech company focusing on the discovery and development of novel targeted medicines to t...
United Kingdom
NorthSea Therapeutics
Clinical-stage biopharmaceutical company focused on the development of structurally engine...
Amsterdam, The Netherland...
Rival Readout
Competing with Tvardi Therapeutics? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Agomab
Unlocking Disease Modification in Fibro-Inflammation
Ghent, Belgium
Alaunos Therapeutics
Attacking solid tumors with TCRs
Houston, United States
AusperBio
Transforming Patient Lives For a Better Tomorrow
San Mateo, United States
Kestrel Therapeutics
We aspire to invent brilliant technologies for difficult cancer targets, beginning with mu...
Watertown, United States
InflaRx
Controlling Inflammation - developing drugs to treat life threatening and chronic inflamma...
Jena, Germany
BBB Therapeutics
Combines existing drugs with it's proprietary for enhanced drug delivery across the blood-...
Leiden, The Netherlands
Dyne Therapeutics
Advancing life-transforming therapies for serious muscle diseases
Waltham, United States
ACELYRIN, INC.
We are a late-stage clinical biopharma company focused on providing life-changing new trea...
Agoura Hills, United Stat...
About Tvardi Therapeutics
Tvardi Therapeutics is a US-based, privately held, clinical-stage biopharmaceutical company established in 2017. The company's slogan, "Breakthrough Medicines for Cancer, Chronic Inflammation & Fibrosis," highlights its mission to develop innovative treatments targeting STAT3, a key mediator in fibrotic signaling pathw...
Development of novel, oral small molecule therapies, Clinical trials for specific diseases, Scientific research and publication
Patients with fibrosis-driven diseases, Patients with inflammatory and proliferative diseases, Healthcare professionals in oncology and pulmonology, Biotech investors
Tvardi Therapeutics, Clinical Stage, Cancer, Chronic Inflammatory Diseases, Fibrotic Diseases, STAT3 Inhibitors, Small Molecule Inhibitors, Phase Ia Dose-escalating Study, TTI-101, Oral Delivery, Societal Impact, Economic Impact, Houston, Texas
B2B, B2B2C
Product Sales, Licensing
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Tvardi Therapeutics: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Tvardi Therapeutics on 11 Sep 2024. The 12 companies listed here were last checked between 28 Jan 2026 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
